Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16706)	3/5/2004 7:24:47 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Interesting, isnt it George. But please take note of this too, that there ARE other Raptiva trials underway other than psoriasis. Not a peep from DNA, SRA or xoma. Also note that xoma pays only 1/8th of other indication development costs but still seems to get that 25% and assumed 6%. Also the Raptiva is dispensed 1 month at a time (not 3) so SPINoza that any way you want. Lastly, the Chiron partnership is GREATLY underestimated at this time. The partnership will run maybe a decade and expect approx. 2 targets a year (they had about 6 to choose from) PSA news due anytime. When the code is broken, then we will know it from a PR. Keepin me fingers crossed. skd etc